Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Discov. 2020 Nov 11;11(2):293–307. doi: 10.1158/2159-8290.CD-20-0263

Figure 4. IL-17 blockade during lung dysbiosis in lung cancer preclinical model.

Figure 4.

a. Experimental conditions (anti-IL-17 or isotype Ab control) were administered to KP mice with lower airway dysbiosis induced by Veillonella parvula. b. anti-IL-17 therapy was associated with decreased tumor burden change during the 2 weeks of antibody injections as compared with isotype control. c. Immune profiling of lung tissue by FACS demonstrates that IL-17 blockade of KP mice with lower airway dysbiosis decrease RORyt+ and Neutrophils (n=6–7 for each experimental condition). d. Immunohistochemistry analysis shows that IL-17 blockade of KP mice with lower airway dysbiosis decrease CD4+/CD8+ T-cells and neutrophils in the non-tumor region (p<0.0001 and p=0.0002, respectively). However, a minimal difference in immune response was seen within the tumor itself (n=8 (LC+dys) vs. n=6 (LC+dys+anti-IL-17) mice/group, each dot represents different region analyzed color-coded by mice).